Integrated use of laboratory services for multiple infectious diseases in the WHO European Region during the COVID-19 pandemic and beyond
Daniel Simões(i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto), Masoud Dara(World Health Organization Regional Office for Europe), Florian P. Maurer(Universität Hamburg), Ana Avellón(Instituto de Salud Carlos III), Askar Yedilbayev(World Health Organization Regional Office for Europe), Lara Vojnov(Clinton Health Access Initiative), Natalia Shubladze(National Center for Tuberculosis and Lung Disease), Anne S. Johansen(Institute of public health of Republic of Macedonia), Maja Stanojević(University of Belgrade), Soudeh Ehsani(World Health Organization Regional Office for Europe), Francis Drobniewski(Queen Mary University of London), Daniela María Cirillo(Vita-Salute San Raffaele University), Roger Paredes(Universitat Autònoma de Barcelona), Irina Felker(Novosibirsk Tuberculosis Research Institute), Nicole Seguy(World Health Organization Regional Office for Europe), Gulmira Kalmambetova
Cited by 9
Related Papers
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
|The Lancet Infectious Diseases|2017|688
Evolution and transmission of drug-resistant tuberculosis in a Russian population
|Nature Genetics|2014|498
Mpox in people with advanced HIV infection: a global case series
|The Lancet|2023|482
Gut Microbiota Linked to Sexual Preference and HIV Infection
|EBioMedicine|2016|480
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
|International Journal of Infectious Diseases|2020|226